What are the current understanding and research on the mechanisms of resistance to treatment in glioblastoma?
Best insight from top research papers
Resistance to treatment in glioblastoma (GBM) is a major challenge in its management. GBM is characterized by heterogeneity and plasticity, which contribute to therapy resistance and recurrence. Glioma stem cells (GSCs) play a crucial role in therapy resistance by promoting tumor heterogeneity and modulating the tumor microenvironment . Mechanisms of resistance include enhanced DNA damage repair, promoter demethylation, autophagy, impaired apoptosis induction, metabolic adaptation, chemoresistance, and immune evasion . The unique biology of GBM cells, such as increased resistance to cell death and the blood-brain barrier, further contribute to treatment resistance . Understanding the mechanisms underlying resistance is essential for developing effective therapeutic strategies. Studies have focused on improving drug delivery to GBM cells, developing novel small molecule drugs, and exploring targeted therapies, immunotherapy, and electric field therapy . Additionally, identifying susceptible targets and combination therapies tailored to the genetically diverse tumor cells in GBM may improve treatment outcomes .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
03 Apr 2023 | The paper discusses the resistance mechanisms to chemotherapy in glioblastoma, specifically focusing on the role of mismatch repair (MMR) components and O6-methylguanine-DNA methyl-transferase (MGMT) expression. It also explores the potential of dianhydrogalactitol (Val-083) as a treatment to overcome these resistance mechanisms. |
21 Apr 2023 | The paper discusses the mechanisms of therapy resistance and treatment failure in glioblastoma, including the activation of key transcription factors and the role of cytokine TNFα in adaptive responses. |
| The paper discusses various mechanisms of resistance to treatment in glioblastoma, including DNA damage repair, MGMT promoter demethylation, autophagy, impaired apoptosis induction, metabolic adaptation, chemoresistance, and immune evasion. | |
| The paper discusses the mechanisms of resistance in glioblastoma, including increased resistance to cell death and the blood-brain barrier limiting the effectiveness of chemotherapy drugs. | |
| The paper discusses the mechanisms of resistance to the chemotherapeutic drug temozolomide (TMZ) in glioblastoma, including inherent insensitivity and acquired resistance during treatment. It also mentions the need for improving drug concentration and developing new targeted drugs. |
Related Questions
What is the role of EBRT in the treatment of glioblastoma?4 answersExternal beam radiotherapy (EBRT) plays a crucial role in the treatment of glioblastoma (GBM). It is one of the effective ways to treat GBM and is commonly used in combination with other therapies. EBRT combined with brachytherapy (EBRT + BT) has shown to have a more pronounced protective effect compared to EBRT alone. The therapeutical effect of EBRT + BT treatment is better, especially in male patients or patients who have undergone local resection. BT, delivered through radioactive isotopes directly into the tumor bed, is a feasible option for extending survival in carefully selected GBM patients. However, the most effective use of BT is likely as a part of multimodal treatment with other novel therapies. Overall, radiotherapy, including EBRT and BT, remains a crucial component in the management of GBM.
What is the newest therapy for glioblastoma?5 answersThe newest therapy for glioblastoma is the use of Aloe-emodin (AE) to induce pyroptosis in GBM cells. AE is a natural compound derived from plants that has shown potential as a pyroptosis booster for GBM therapy. However, the administration of AE is challenging due to the blood-brain barrier (BBB) and its non-selectivity. To overcome this obstacle, AE@ZIF-8 NPs, a biomineralized nanocarrier, has been developed. This nanocarrier releases AE in response to the tumor's acidic microenvironment (TAM) and has been further modified with transferrin (Tf) and polyethylene glycol-poly (lactic-co-glycolic acid) (PEG-PLGA) to improve BBB penetration and tumor targeting. The use of AE-NPs (Tf-PEG-PLGA modified AE@ZIF-8 NPs) has shown promising results in enhancing GBM pyroptosis, increasing intracranial distribution, tumor tissue accumulation, and activating antitumor immunity while reducing AE-related toxicity.
What is the typical duration between treatment and progression of glioblastoma multiform?5 answersThe typical duration between treatment and progression of glioblastoma multiforme (GBM) varies. In one study, the minimum period of early progression was 0.33 months, while the maximum was 4.27 months, with a median of 1.1 months. Another study reported a median progression-free survival (PFS) of 12 months for GBM patients treated with surgery followed by radiotherapy and chemotherapy. However, it is important to note that GBM can progress rapidly, with a doubling time of 10 days in some cases. Overall, the duration between treatment and progression of GBM can range from a few weeks to several months, highlighting the need for close monitoring and individualized treatment approaches.
What's the cell ratio in glioblastoma?3 answersThe cell ratio in glioblastoma is not explicitly mentioned in the abstracts provided.
What are the challenges in glioblastoma?3 answersGlioblastoma faces several challenges in its treatment. These challenges include inadequate drug delivery across the blood-brain barrier, intra- and intertumoral heterogeneity, redundant signaling pathways, and an immunosuppressive microenvironment. The tumor microenvironment in glioblastoma is uniquely immunosuppressive, which blunts immune responses and makes it difficult to control tumor growth and recurrence. Efforts have been made to explore immunotherapeutic strategies for glioblastoma, but there is still a long road ahead for their broad application. The anatomy and physiology of brain tumors, including the blood-brain barrier, also pose challenges in delivering adequate drug therapy to the central nervous system. Additionally, the presence of the blood-brain barrier and significant heterogeneity within gliomas make the development of effective diagnostics and therapeutics challenging.
How do you treat a glioblastoma?3 answersTreatment for glioblastoma typically involves surgical resection to reduce tumor volume, followed by adjuvant radiotherapy and chemotherapy. The current standard of care includes temozolomide chemotherapy given during radiotherapy, followed by maintenance chemotherapy with temozolomide and the addition of tumor-treating fields. At relapse, there is limited evidence for interventions that improve outcomes, but nitrosourea-based chemotherapy, such as lomustine, is commonly used. Bevacizumab can prolong progression-free survival but not overall survival and is not approved in the European Union. Immunotherapy remains experimental, with drugs such as nivolumab, depatuxizumab, and marizomib in advanced clinical development. Physical methods, such as fluorescent-guided surgery and tumor-treating fields therapy, have shown positive results and are incorporated into standard management. Other techniques, including photodynamic therapy and focused ultrasound, are being clinically developed. Personalized treatments and cancer vaccination are also being explored as new therapeutic approaches.